Xilio Therapeutics Launches Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Reaches $17.5 Million Development Milestone in Exclusive Partnership with Gilead
Efarindodekin Alfa Clinical Trial: Xilio Therapeutics has initiated patient dosing in Phase 2 of a clinical trial for efarindodekin alfa (XTX301), a tumor-activated IL-12, after demonstrating promising anti-tumor activity and a well-tolerated safety profile in Phase 1.
Financial Milestone Achievement: The company achieved a $17.5 million development milestone under its license agreement with Gilead Sciences, extending its cash runway into the first quarter of 2027, with current cash and equivalents reported at $121.6 million.
Discover Tomorrow's Bullish Stocks Today
Analyst Views on XLO
About XLO
About the author
Xilio Therapeutics, Inc. (XLO) Announces Q3 Loss and Falls Short of Revenue Projections
Quarterly Performance: Xilio Therapeutics reported a quarterly loss of $0.03 per share, matching expectations, and significantly improved from a loss of $0.22 per share a year ago, while revenues of $19.07 million fell short of estimates by 28.51%.
Stock Outlook: The company's shares have declined by 19% this year, contrasting with the S&P 500's 16.5% gain, and the stock currently holds a Zacks Rank #3 (Hold), indicating expected performance in line with the market.
Earnings Estimates: The consensus EPS estimate for the upcoming quarter is -$0.12 on revenues of $7.96 million, with a fiscal year estimate of -$0.45 on $45.65 million in revenues, reflecting mixed trends in earnings estimate revisions.
Industry Context: Xilio operates within the Medical - Biomedical and Genetics industry, which ranks in the top 35% of Zacks industries, suggesting that industry performance could significantly influence the stock's future.
Xilio Therapeutics Unveils Late-Breaking Phase 2 Results for Vilastobart in MSS mCRC Patients with Elevated Plasma Tumor Mutational Burden at the 40th Annual SITC Meeting
Clinical Trial Results: Xilio Therapeutics reported a 40% objective response rate (ORR) in heavily pre-treated patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC) without liver metastases and high plasma tumor mutational burden (TMB) in their Phase 2 trial of vilastobart combined with atezolizumab.
Plasma TMB as a Biomarker: Approximately 55% of patients with MSS CRC are estimated to have high plasma TMB, indicating a significant population that may benefit from the combination treatment, highlighting the potential of plasma-based TMB as a predictive biomarker for response.
Safety Profile: The combination therapy of vilastobart and atezolizumab demonstrated a well-tolerated safety profile, with most treatment-related adverse events being Grade 1 or 2, and only a small percentage of patients discontinuing treatment due to adverse effects.
Future Plans: Xilio is seeking partnerships to further develop vilastobart in combination with PD-(L)1 or PD1-VEGF therapies for MSS CRC and other tumor types, following the promising results from the clinical trial.
